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Abstract
Background: Congenital diaphragmatic hernia (CDH) is a life-threatening developmental 
anomaly, intrinsically combining severe pulmonary hypoplasia and hypertension. During 
development, signal transducers and activators of transcription (STAT) are utilized to elicit 
cell growth, differentiation, and survival. Methods: We used the nitrofen-induced CDH rat 
model. At selected gestational time points, lungs were divided into two experimental groups, 
i.e., control or CDH. We performed immunohistochemistry and western blotting analysis to 
investigate the developmental expression profile of the complete family of STATs (STAT1-6), plus 
specific STATs activation (p-STAT3, p-STAT6) and regulation by SOCS (SOCS3) in normal lungs 
against those of diseased lungs. The normal fetal lung explants were treated with piceatannol 
(STAT3 inhibitor) in vitro followed by morphometrical analysis. Results: Molecular profiling 
of STATs during the lung development revealed distinct early and late expression signatures. 
Experimental CDH altered the STATs expression, activation, and regulation in the fetal lungs. 
In particular, STAT3 and STAT6 were persistently over-expressed and early over-activated. 
Piceatannol treatment dose-dependently stimulated the fetal lung growth. Conclusion: These 
findings suggest that STATs play an important role during normal fetal lung development 
and CDH pathogenesis. Moreover, functionally targeting STAT signaling modulates fetal lung 
growth, which highlights that STAT3 and STAT6 signaling might be promising therapeutic 
targets in reducing or preventing pulmonary hypoplasia in CDH.
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Introduction
Congenital diaphragmatic hernia (CDH) is a life-threatening developmental anomaly. Its 
clinical management highly impacts the outcome of vulnerable patients and still remains 
challenging for the involved medical specialists [1-3]. In CDH, an incomplete diaphragm fails 
to separate the thoracic and abdominal cavities during development. This diaphragmatic 
malformation causes the abdominal viscera to invade the thorax, irretrievably impairing 
proper growth and development of the lungs. Concomitantly with herniation, severe 
pulmonary hypoplasia and pulmonary hypertension (PH) develop [4, 5]. In fact, these 
have proven to be the most complex aspects to therapeutically address in CDH [6, 7]. The 
nitrofen animal model has contributed extensively to CDH research. It is well-established 
that administering nitrofen, formerly used as an herbicide, to pregnant rodents at an early 
gestational time induces fetal defects that closely resemble those observed in human CDH 
[8-10].
Normal lung development is commanded by complex signaling cascades and rigorous 
molecular control. Pivotal developmental processes such as temporal-spatial organization, 
cellular proliferation, differentiation, and death are instructed by transcriptional programs 
[11-13]. The signal transducer and activator of transcription (STAT) family of transcription 
factors have a broad range of roles in development. The STAT pathway is the selected signaling 
route for numerous cytokines and growth factors crucial for proper lung development [14-
17]. Classically, when such ligands interact with its receptor, latent STATs residing in the 
cytoplasm are recruited to the receptor followed by STAT activation that is induced through 
tyrosine kinase mediated phosphorylation, namely Janus kinases (JAKs). The activated STATs 
are then released from the receptor to interact with other STATs in order to form homo- 
or hetero-dimers, which are capable of nuclear translocation and specific binding to DNA. 
They ultimately activate or repress transcription of targeted genes [18-20]. Normal STAT 
activation must be maintained as a transient cellular response, therefore it is conveniently 
controlled by physiological negative regulators, such as the family of suppressors of cytokine 
signaling (SOCS). These proteins are induced by JAK-STAT activation, and they inhibit the 
same cascade afterwards thus creating a negative feedback loop [21-23].
Therefore, in this study, a preliminary investigation is conducted to establish the presence 
and distribution of STAT family during normal fetal lung development, given that thorough 
evidence in fetal lung models is manifestly lacking. The developmental expression profiles of 
all the members of the STAT family (STAT 1-6) are addressed in the normal developing lung 
as well as the pathological setting of CDH. Specific STATs activation and regulation by SOCS 
were also assessed in both normal and diseased lungs. Finally, the functional significance of 
STAT signaling in lung development was investigated by assessing the effect of STAT pathway 
inhibition in normal fetal lung growth.
Materials and Methods
Ethical Approval
This study was carried out in strict accordance with the recommendations in the ‘Guide for the Care 
and Use of Laboratory Animals,’ published by the US National Institutes of Health (NIH Publication No.85-
23, revised 1996). Animal experiments were performed according to the Portuguese law for animal welfare 
(Diário da República, Portaria 1005/92) and were subjected to internal institutional ethical review (DGV 
022162 - 520/000/000/2006). Moreover, all efforts were made to minimize animal suffering.
Animal model and experimental design
Sprague-Dawley female rats (225 g; Charles-River, Spain) were maintained in appropriate cages 
under controlled conditions and fed with commercial solid food. According to the nitrofen-induced CDH 
rat model [24, 25], pregnant rats were treated either with 100 mg of nitrofen (2, 4-dichlorophenyl-p-
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nitrophenylether) dissolved in olive oil or olive oil alone. At selected time points, i.e., 15.5, 17.5, 19.5, and 21.5 
days postconception (dpc), fetuses were delivered by cesarean section to inspect the diaphragm and harvest 
the lungs. Fetuses were divided into two groups, namely, control group (Control) with fetuses exposed to 
olive oil alone and CDH group (CDH) with those exposed to nitrofen with CDH. Regarding this experimental 
design, undoubtedly assessment of CDH by surgical inspection at 15.5 dpc is impractical. Therefore, for 
this early gestational age, CDH group refers to the fetuses exposed to nitrofen (independently of CDH 
development) and control group refers to those that are not exposed to nitrofen. Lungs were either snap-
frozen in liquid nitrogen for protein extraction or fixed in 4% paraformaldehyde for immunohistochemistry.
Immunohistochemistry
Immunostaining was performed on paraformaldehyde-fixed and paraffin-embedded excised lungs and 
embryos of different gestational ages (15.5 - 21.5 dpc) as previously described [26-28]. Primary antibodies 
for STAT1 (1:200, Abcam Inc., UK), STAT2 (1:50, Abcam Inc.), STAT3 (1:50, Cell Signaling Technology Inc., 
USA), STAT4 (1:50, Cell Signaling Technology Inc.), STAT5 (1:50, Santa Cruz Biotechnology Inc., USA), and 
STAT6 (1:50, Abcam Inc.) were used. Negative control reactions included omission of the primary antibody 
and the simultaneous omission of the primary and secondary antibodies. In both the cases, immunoreactive 
staining was not observed. Sections were incubated with a labeled streptavidin-biotin immunoenzymatic 
antigen detection system (UltraVision Large Volume Detection System Anti-Polyvalent, Horseradish 
Peroxidase, Lab Vision Corporation, USA) according to the manufacturer’s instructions. At least three 
independent experiments were performed for each antibody tested. In each experiment, a different set of 
slides (duplicates included, two sections from the same individual, per slide) comprising the whole range of 
gestational ages plus the adult were used. Different and unrepeated animal samples were selected for each 
group (gestational age). Six different animals for each group per studied antibody were examined.
Western blot analysis
Pooled tissue samples (n=3 subjects from the same litter, per sample) of both experimental groups at 
the selected gestational ages were processed for Western blot analysis. Proteins were obtained according 
to Kling et al [29]., and the protocol was performed as previously described [28]. Blots were probed with 
antibodies to STAT1 (1:2000, Cell Signaling Technology Inc.), STAT2 (1:2000, Abcam Inc.), STAT3 (1:2000, 
Cell Signaling Technology Inc.), STAT4 (1:1000, Cell Signaling Technology Inc.), STAT5 (1:2000, Cell Signaling 
Technology Inc.), STAT6 (1:2000, Abcam Inc.), phospho-STAT3 (1:1000, Cell Signaling Technology Inc.), 
phospho-STAT6 (1:1000, Cell Signaling Technology Inc.), and SOCS3 (1μg/mL; Abcam Inc.) according to the 
manufacturer’s instructions. For loading control, blots were probed with β-tubulin (1:150000, Abcam Inc.), 
and the quantitative analysis was performed with Quantity One 4.6.5 1-D Analysis Software (Bio-Rad). For 
analysis of each antibody, at least three independent experiments were performed (n=3) in each experiment 
an unrepeated pooled sample was used. In total, nine animals were used in each group (gestational age/
condition) per antibody.
Fetal lung explant culture
Lungs were removed from 13.5 dpc embryos, harvested, and dissected in DPBS (Lonza, Switzerland) 
under a stereomicroscope (SZX16, Olympus). Then, the lungs were transferred to porous membranes 
(Isopore™ membrane filters, Merck Millipore, Germany) and cultured for 4 days as previously described [28, 
30]. The culture medium was replaced every 48 hours. Cultures were supplemented daily with several doses 
of piceatannol (Calbiochem®, Merck Millipore) ranging from 0.1 to 30 ng/mL (n=9 for each dose tested), 
and 0.1% dimethylsulfoxide (DMSO) was used as control condition (n=12). Three independent experiments 
were performed and the explants were randomly assigned a culture condition.
Morphometric analysis
Branching morphogenesis was monitored daily by photographing the explants using a stereomicroscope 
equipped with a camera (DP71, Olympus). At day 0 (D0: 0 h) and day 4 (D4: 96 h) of culture, the total 
number of peripheral airway buds and the epithelial perimeter in all lung explants were determined using 
the Image J image processing and analysis software (version 1.44, USA). For all experimental conditions, the 
results were expressed as D4/D0 ratio.
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Statistical analysis
All quantitative data are presented as mean ± SEM. The statistical analysis was performed by two-way 
ANOVA for lung condition (normal and CDH) and gestational age (15.5, 17.5, 19.5, and 21.5 dpc) on protein 
expression level. One-way ANOVA was performed on the number of peripheral airway buds or epithelial 
perimeter on piceatannol concentration (0.1, 1, 10, 20, 30 ng/mL). The parametric test assumptions were 
previously verified, and an additional Holm-Sidak test was used for post-test analysis. Statistical software 
SigmaStat (version 3.5; Systat Software Inc., USA) was used in all procedures. Statistical significance was set 
at p˂ 0.05.
Results
STATs expression pattern during rat fetal lung development
Immunohistochemical studies were performed in order to assess the protein presence 
and tissue distribution of STAT1, 2, 3, 4, 5 and 6 during rat normal pulmonary development 
at the selected gestational ages, i.e., 15.5, 17.5, 19.5 and 21.5 dpc. Analysis of normal adult 
tissue was also performed. Immunohistochemistry revealed that all members of this family 
of proteins are expressed in the developing normal rat lung as well as the adult (Fig. 1). 
Most STATs, namely STAT1 (Fig. 1A-E), STAT2 (Fig. 1F-J), STAT4 (Fig. 1a-e), and STAT5 (Fig. 
1f-j), have early widespread expression in the primitive tissues that constitute the lung at 
15.5, 17.5 and 19.5 dpc. Nonetheless, as the tissues progressively differentiate, particularly 
towards the 21.5 dpc term, their expression becomes predominant in epithelial cells of 
the airways. Mesenchymal STAT3 expression is more restricted to peri-bronchial regions 
at early 15.5 dpc. Prominent nuclear staining of STAT3 is observable from early gestation 
Fig. 1. Protein expression pattern of signal transducers and activators of transcription (STAT) family 
members (STAT1- 6) during fetal rat lung development. Representative immunohistochemical evidence for 
the presence of (A-E) STAT1, (F-J) STAT2, (K-O) STAT3, (a-e) STAT4, (f-j) STAT5 and (k-o) STAT6 throughout 
lung development, from early 15.5 dpc until late 21.5 dpc, and also in the adult. Original magnification 100×.
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until term and is particularly associated with the epithelial tissue at late gestational ages 
(Fig. 1K-O). Lastly, STAT6 is detected early at 15.5 dpc mainly in the undifferentiated 
mesenchyme. Its expression remains extensively noticeable in this tissue and also in the 
epithelium as the pulmonary development progresses (Fig. 1k-o). Concerning the adult rat 
lung tissue, the immunostaining is mostly restricted to the epithelial lining of the bronchial 
Fig. 2. Experimental CDH alters STATs protein expression and induces early activation of STAT3 and STAT6 
in fetal lung development. Western blot analysis of STAT1-6 and phosphorylated STAT3 and STAT6 protein 
levels in normal fetal lungs (Control) and experimental CDH fetal lungs (CDH) at selected gestational ages 
from 15.5 to 21.5 dpc. (A) Representative immunoblots are shown. Each lane represents a pooled-tissue 
sample, and relative expression was determined against β-tubulin. (B) Semi-quantitative analysis of three 
independent experiments for each STAT is plotted. Results are presented as mean ± SE. Symbols indicate 
main effects and non-redundant interactions of the factorial ANOVA. p< 0.05. * CDH vs. Control; # 15.5 dpc 
vs. 17.5/19.5/21.5 dpc; (#) 15.5 dpc vs. 21.5 dpc; ¥ 17.5 dpc Control vs. 21.5 dpc Control; † 21.5 dpc vs. 
15.5/17.5/19.5 dpc; ‡ 21.5 dpc Control vs. 15.5 dpc Control; § 21.5 dpc CDH vs. 21.5 dpc Control.
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airways and alveoli, with predominant 
nuclear localization. This revealed to be 
a consistent observable feature in all the 
members of this transcription factors 
family.
Experimental CDH alters STATs 
protein expression in fetal lung 
development
STATs protein expression profiling 
in lung development was assessed 
by Western blot in normal and 
nitrofen-induced CDH rat lungs at the 
aforementioned gestational ages (Fig. 
2). Forthwith analysis mainly revealed 
two distinct expression profiles for these 
proteins in lung development (Fig. 2B). 
On one hand, some STATs presented a low 
level of expression at an early gestation 
of 15.5 dpc, which remains stable until 
the later gestational age studied (21.5 
dpc), that corresponds to an observable 
peak of expression. This is found to be 
the case of STAT1, STAT4, and STAT5 
expression levels in both normal and 
experimental CDH fetal lungs throughout 
development (Fig. 2B, top left and central 
plots). During development of both 
normal and CDH-induced lungs, STAT1, 
STAT4 and STAT5 expression levels at 
late gestation (21.5 dpc) are significantly 
higher than all the other gestational ages 
(p<0.001). Exceptionally for STAT4, at 
21.5 dpc, CDH lungs exhibit even higher 
expression than the already observed 
high expression in normal lungs at 
this gestational age, being such levels 
significantly different (p=0.032). On the 
other hand, a couple of STATs presented 
the highest level of expression at a very 
early gestational age, 15.5 dpc, which 
immediately drops to lower levels and continues to remain low until term, 21.5 dpc. This is 
observed in STAT3 and STAT6, interestingly only in normal fetal lungs. In experimental CDH, 
the expression levels of both the proteins are elevated throughout all the studied gestational 
ages and are significantly different compared to the normal fetal lungs (Fig. 2B, plots below 
dashed line). The effect of experimental CDH in STAT3 and STAT6 expression is, therefore, 
statistically significant (p≤0.01). Regarding STAT6 expression at 15.5 dpc, protein levels are 
significantly higher than those in any other studied gestational age (p=0.011) (Fig. 2B, below 
dashed line, top right). Furthermore, STAT2 normal protein expression during development 
resembles STAT1, STAT4, and STAT5, which is characterized by low expression levels at 
early gestation and high levels at term. It is further substantiated by the significantly higher 
expression at 21.5 dpc compared to that at 15.5 dpc (p=0.005). Conversely, in CDH lungs at 
21.5 dpc, STAT2 expression decreases significantly in comparison to normal lungs (p=0.009) 
(Fig. 2B, top right).
Fig. 3. Experimental CDH induced overexpression of 
SOCS3 in fetal lung development. Western blot analysis 
of SOCS3 protein levels in normal fetal lungs (Control) 
and experimental CDH fetal lungs (CDH) at selected 
gestational ages from 15.5 to 21.5 dpc. (A) Representative 
immunoblots are shown. Each lane represents a pooled-
tissue sample and relative expression was determined 
against β-tubulin. (B) Semi-quantitative analysis of 
three independent experiments for SOCS3 is plotted. 
Results are presented as mean ± SE. Symbols indicate 
main effects and non-redundant interactions of the 
factorial ANOVA. p< 0.05. * CDH vs. Control; † 21.5 dpc 
vs. 15.5/17.5/19.5 dpc.
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Experimental CDH induced early activation of STAT3 and STAT6 in fetal lung development
Since overexpression of STAT3 and STAT6 was observed in CDH-induced fetal lungs, 
the activation status of both transcription factors was investigated in this condition and also 
in normal developing lungs (Fig. 2). Immunoblot analysis of the levels of phosphorylated 
STAT3 (p-STAT3) indicated that there is a significant difference in CDH-induced lungs during 
development compared to normal ones (p=0.032) (Fig. 2B, below dashed line, bottom left 
plot). Likewise, the same significant difference was observed regarding phosphorylated STAT6 
(p-STAT6) levels (p=0.009) (Fig. 2B, below dashed line, bottom right plot). Experimental 
CDH induces activation of these two transcription factors since increased phosphorylation of 
STAT3 and STAT6 is largely observed during gestation and is particularly significant in early 
gestational ages of pulmonary development.
Distinctly, p-STAT6 expression levels in both normal and CDH-lungs are significantly 
higher at the earliest studied gestational age, 15.5 dpc (p=0.003), compared to the latest 
gestational age at 21.5 dpc, which presents the lowest levels of expression, indicating an 
effect of gestation time on the phosphorylation status of this transcription factor.
Normal developing lungs present relatively low levels of phosphorylation of these two 
STATs, particularly residual in some gestational ages. For instance, the p-STAT3 expression 
Fig. 4. STAT inhibition, by piceatannol, dose-dependently increased fetal lung growth. (A) Upper panel is 
representative of untreated lung explants (Control) and lung explants treated with vehicle (DMSO) at day 4 
(D4); the bottom panel represents lung explants treated with several piceatannol concentrations (PIC) on 
day 4 (D4). All images are at same magnification. Scale bar = 6349 µm. (B) Morphometric analysis of the 
number of peripheral airway buds and epithelial perimeter of fetal rat lung explants supplemented with 
increasing concentrations of piceatannol. Results are expressed as the D4/D0 ratio. p< 0.05. * vs. DMSO; ¥ vs. 
0.1; ‡ vs. 1; † vs. 10; ¤ vs. 20 ng/mL.
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levels drop considerably at a specific gestational age of 17.5 dpc, being significantly lower 
(p= 0.006) than the gestational age with the highest expression level detected at 21.5 dpc.
Experimental CDH induced over-expression of SOCS3 in fetal lung development
To further explore our findings on STATs signaling in experimental CDH, the contribution 
of SOCS3 to STATs regulation during lung development was determined by Western blot 
analysis (Fig. 3). In both CDH-induced and normal lungs, a gradual increase in SOCS3 
expression is detected, as lung development progresses, that culminates in a late gestational 
peak of expression. Consequently, SOCS3 expression levels at 21.5 dpc are significantly higher 
than all the other gestational ages (p<0.001). Also, despite sharing a similar SOCS3 expression 
trend, CDH lungs significantly differed from normal lungs (p=0.04), and experimental CDH 
induced an increase of SOCS3 expression (Fig. 3B).
STAT inhibition, by piceatannol, increased fetal lung growth in a dose-dependent manner
We functionally assessed the effect of STAT pathway inhibition on fetal lung growth 
by supplementing 13.5 dpc fetal lung explant cultures with piceatannol (STAT3 inhibitor). 
When added to the culture medium, piceatannol significantly stimulated fetal lung growth 
in a dose dependent manner (Fig. 4). Lower doses of piceatannol at 1 and 10 ng/mL have 
an enhancing effect on lung growth in a dose-dependent manner, with 10 ng/mL having 
the most significant growth stimulatory effect. Morphometric analysis of lung explants, 
supplemented with 10 ng/mL, showed a significantly higher number of peripheral airway 
buds compared to both DMSO control (p< 0.001) and the lower doses of 0.1 and 1 ng/mL (p< 
0.001 and p= 0.002, respectively). It also showed a significantly higher epithelial perimeter 
compared to both DMSO control (p= 0.028) and the lowest dose tested (0.1 ng/mL) (p= 
0.019). In these culturing conditions, the optimum concentration of the compound is 10 ng/
mL. At higher doses, the piceatannol effect on lung explant growth is comparatively more 
moderate. Particularly at 30 ng/mL, the number of peripheral airway buds and the epithelial 
perimeter are significantly reduced compared to the optimal dose of 10 ng/mL (p< 0.001, p= 
0.034, respectively). However, no morphometric values significantly lower than DMSO were 
observed.
Discussion
STAT proteins instruct key cellular processes, namely growth, differentiation, and 
survival [18, 20]. Despite our broad understanding of the transcriptional control of lung 
branching morphogenesis by other families of transcription factors [11, 13], both expression 
and role of STATs remain unclear in lung development.
Our study provides evidence for a developmental expression pattern of all the members 
of STAT family of transcription factors in the lung. All studied members of this family of 
proteins are herein described to be constitutively expressed in fetal pulmonary tissues since 
early development. We also detail STATs tissue distribution in the developing lung. In general, 
STAT family members have diffuse protein expression in the primitive pulmonary tissue; 
however, as development progresses, these proteins gradually display expression specificity 
towards the pulmonary epithelium (Fig. 1). Therefore, by the end of gestation, fetal STATs 
distribution resembles the tissue distribution observed in the adult lung, mainly restricted 
to the epithelial lining of the bronchi and alveoli, with predominant nuclear distribution. 
The results shown in the present study contribute to the demonstration of the early and 
continuous presence as well as a dynamic distribution pattern of STAT members throughout 
the developmental stages of the lung, suggesting that this family of transcription factors has 
multiple functions in lung development. In agreement with it, previous findings also support 
diverse roles for STATs in the normal developmental processes of different organs, including 
branching organs [14, 31-35].
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We also detected a particular immunolocalization pattern regarding STAT3 at 15.5 
dpc; this pattern is noticeable for differing from the widespread expression observed for 
most STATs at early gestation. Specifically, at this gestational age, STAT3 expression is 
restricted to the mesenchyme surrounding the primitive respiratory tract, including lung 
bud tips. In the rat, 15.5 dpc is representative of the pseudoglandular stage, during which 
the embryonic lung essentially undergoes branching morphogenesis, conducted by signaling 
interactions that occur locally at the distal lung buds. STAT3 distribution in the lung, during 
the pseudoglandular stage, is compatible with this distal bud signaling center suggesting 
an underlying role of STAT3 in early branching morphogenesis. Recently, Carraro et al. 
suggested that stabilization of STAT3 RNA expression during the pseudoglandular stage 
may be important for correct branching morphogenesis [36]. Previous studies have also 
implicated STAT3 in lung branching morphogenesis [26], and a consistent downstream of 
STAT3 activation was observed in response to the inhibitory actions of cytokines on fetal 
lung branching [27].
Several families of transcriptional factors have been strongly implicated in the etiology 
of congenital diaphragmatic hernia [37, 38]. In the present study, we investigated the 
pulmonary protein expression levels of the STAT family members in both normal and 
nitrofen-induced CDH rat lungs during representative stages of lung development (Fig. 
2). Firstly, our observations evidenced a dynamic temporal expression pattern of STAT 
proteins during normal fetal lung development. Most members of this family share a similar 
expression pattern in normal lungs. STAT1, STAT2, STAT4, and STAT5 have their lowest 
expression at early gestation and the highest expression by the end of gestation, indicating an 
increasing requirement of these transcription factors as pulmonary development progresses. 
Normal mammalian lung development proceeds towards increasing pulmonary epithelial 
cell proliferation and differentiation. This underlines that the current findings on STATs 
expression pattern are in agreement with our previous observation, i.e., STATs distribution 
is more restricted to epithelial pulmonary tissue at the latest studied gestational ages.
Similarly to normal fetal lungs, some STATs in CDH lungs, namely STAT1, STAT4, and 
STAT5, present a low level of expression at early gestation (15.5 dpc), which remains stable 
until the later studied gestational age (21.5 dpc), where a peak of expression is observed. 
On the contrary, STAT2 in CDH lungs strongly differs from normal lungs at 21.5 dpc since its 
expression is markedly decreased. This observation at late-gestation most likely represents 
a mechanistic-side effect of disease progression. It is worth noting that STAT2 is a pivotal 
component of the IFN-induced transcriptional machinery and mediates anti-growth and 
apoptotic effects [39, 40]. Moreover, IFN-α was demonstrated to be significantly increased 
in newborns with CDH [41]. Considering all these observations, one question that remains 
unexplored is whether CDH progression causes disturbances in the IFN-α -STAT2 signaling 
axis. Interestingly, prior studies have evidenced that persistent exposure to IFN-α led to 
resistance to type I IFN–induced apoptosis due to loss of STAT2 expression [42].
In the present study, we also found that STAT3 and STAT6 are expressed differently. It is 
noteworthy that our results show a specific modulation of STAT3 and STAT6 expression in the 
context of CDH since these proteins are persistently overexpressed during the development 
of diseased lungs. However, the other STATs expression levels remain unchanged or only are 
mildly modified compared to normal lungs. These findings highlight a conditional association 
between STAT3 and STAT6 persistent overexpression in CDH. It also uncovers an important 
role for of these two transcription factors in the pathogenic events of this congenital lung 
disease. In addition to the overexpression of these STATs, a concomitant CDH-induced 
hyperactivation of these two transcription factors was observed in the developing lung 
evident mostly in the early gestational ages (15.5 and 17.5 dpc). Thus, reinforcing that STAT3 
and STAT6 signaling may contribute to the modifications of gene expression underlying the 
CDH pathogenesis (Fig. 2). In agreement with our findings, a recent report provided evidence 
of an increased STAT3 activation in CDH, particularly in pulmonary vasculature [43]. 
Furthermore, dysregulated activation of STAT proteins is implicated in several pathological 
conditions, particularly STAT3 and STAT6 [44-48], which makes the prospect of targeting the 
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JAK–STAT pathway therapeutically appealing.
Our results also evidenced that the expression of SOCS3, a negative feedback inhibitor 
of STAT signaling, is higher in CDH subjects (Fig. 3). Given that SOCS protein expression has 
been shown to be STAT-dependent, and SOCS genes are target genes of STATs and get induced 
by active JAK-STAT signaling [21], altered SOCS3 expression was expected and is indicative of 
a regulatory role of SOCS3 in CDH. In many pathological circumstances, increased expression 
of SOCS proteins coincides with the activation of JAK/STAT pathways [21, 49-51]. Collectively, 
our data provide the first evidence for a previously unappreciated regulatory mechanism 
occurring in the pathological development of experimental CDH.
Taken together, these observations urged us to investigate the functional outcome of 
STAT pathway inhibition in the developing lung and assess its effect on normal fetal lung 
growth in vitro. Rat fetal lung explants at 13.5 dpc cultured in the presence of piceatannol, 
a known STAT3 signaling inhibitor [52, 53], exhibited a clear increase in growth in a dose-
dependent manner (Fig. 4). Piceatannol has been widely used to effectively inhibit STAT3 
phosphorylation [54-56]; nevertheless, it is possible that the effects of piceatannol other 
than STAT3 inhibition may have contributed to its ability to interfere with fetal lung growth. 
For example, besides JAK1 kinase, piceatannol is also reported to inhibit SYK kinase, as well 
as other transcription factors, namely nuclear factor-kB (NF-kB). Therefore, further studies 
are necessary to support the pharmacological approach of STAT3 inhibition. Herein, it is 
demonstrated that precise regulation of STAT signaling is necessary for proper fetal lung 
growth during early development, revealing an unanticipated role of STAT signaling during 
lung branching morphogenesis. Even though STAT transcription factors have been largely 
overlooked in lung development, STAT3 has been previously implicated in the regulation of 
developmental processes [14-17], namely lung branching [26, 27, 36], which is consistent 
with our findings. More importantly, we show that modulation of fetal lung growth can 
be achieved by conditionally targeting STAT signaling, though the detailed mechanistic 
interactions are yet to be fully defined.
Till date the pathogenesis of CDH has not been fully established; nonetheless, the current 
expertise consensually regards the retinoid-signaling disruption as a contributing factor 
[57-59]. Strikingly, previous observations suggest that there may be a significant functional 
cross-talk between STAT and retinoic acid receptor (RAR) families of transcription factors. 
For example, a fusion protein STAT5-RARalpha was identified and demonstrated to have an 
enhancing effect on STAT3 transcriptional activity in promyelocytic leukemia [60]. The same 
authors presented a model of enhancement of STAT3 transcriptional activity and its effect 
on apoptosis being modulated by the presence/absence of retinoic acid (RA) [61]. In normal 
hematopoiesis, STAT5 and RAR associate in vivo in a cytokine-dependent manner [62]. Glioma 
cells also display an increased STAT3 activation upon RA treatment [63]. More importantly, 
in respiratory epithelial cells, besides the protein-protein interaction, STAT3 and RAR were 
found to act synergistically in regulating surfactant protein B [64, 65]. It would be important 
in pursuing a more comprehensive perspective on CDH pathogenesis to understand the 
nature of the molecular interaction between STAT and RAR family members as well as their 
functional outcomes. An intriguing possibility is that retinoid signaling disruption could lead 
to inappropriate STAT activation in CDH, particularly STAT3 and STAT6. Following this line 
of reasoning, these transcription factors could play a role in the primary events determining 
the onset of the disease. Lung development is complex, and highly dependent on the timely 
interplay of molecular signals and their tight regulation. The identification of important 
regulators, such as transcription factors, and how their pathways are disrupted in lung 
diseases like CDH are essential for the development of successful therapies.
Importantly, the novel data presented herein provides direct evidence that all STAT 
proteins are constitutively expressed in fetal pulmonary tissue since early development. 
Experimental CDH alters STATs protein expression, activation, and regulation in the fetal 
lung, as demonstrated by the persistent overexpression of STAT3 and STAT6 and their 
early overactivation combined with SOCS3 overexpression in diseased fetal lungs (Fig. 5). 
These findings stress previously unappreciated disturbances of pulmonary developmental 
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signaling pathways, such as STAT, in CDH. Moreover, compelling evidence is presented that 
targeting STAT signaling through STAT3 inhibition impacts the fetal lung growth in vitro. 
This suggests that precise STAT signaling regulation may be important during normal fetal 
lung development. While presented evidence is still far from providing any efficient lung 
growth modulation strategy, further functional studies would greatly aid in addressing the 
therapeutic potential of targeting active STATs. Clearly, this work supports a role of these 
specific molecular mediators in the complex pathophysiological aspects of CDH development.
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